Timothy K Nguyen1, Arjun Sahgal1, Jay Detsky1, Eshetu G Atenafu2, Sten Myrehaug1, Chia-Lin Tseng1, Zain Husain1, Chris Heyn3, Pejman Maralani3, Mark Ruschin1, James Perry4, Hany Soliman1. 1. Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 2. Department of Biostatistics, University Health Network, University of Toronto, Toronto, Ontario, Canada. 3. Department of Neuroradiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 4. Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS: Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed from a prospectively maintained database. Radiographic patterns of LMD were classified as focal classical, diffuse classical, focal nodular, and diffuse nodular. RESULTS: HSRT was delivered, most commonly 30 Gy in 5 fractions, to 320 intracranial lesions (57% intact and 43% surgical cavities) in 235 patients. The median follow-up was 13.4 months (range, 0.8 to 60 mo). LMD developed in 19% of patients with a 1-year LMD rate of 12%. From the diagnosis of LMD, the median overall survival (OS) was 3.8 months (range, 2-20.8 mo). The most common LMD pattern was diffuse nodular (44%). No difference in OS was observed between LMD patterns (P = 0.203). Multivariable analysis identified surgical cavities at significantly higher risk of LMD compared with intact lesions (odds ratio [OR] = 2.30, 95% CI: 1.24, 4.29, P = 0.008). For cavities, radiosensitive tumors (OR = 2.35, 95% CI: 1.04, 5.35, P = 0.041) predicted for LMD, while, for intact metastases, patients receiving treatment with targeted agents or immunotherapy (TA/I) were at lower risk (OR = 0.178, 95% CI: 0.04, 0.79, P = 0.023). CONCLUSIONS: Patients who had a brain metastasis resected were at an increased risk of LMD. OS was poor despite treatment of LMD, and no differences in OS based on the pattern of LMD was observed. Treatment with TA/I was observed to be protective against LMD and requires further study.
BACKGROUND: The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS:Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed from a prospectively maintained database. Radiographic patterns of LMD were classified as focal classical, diffuse classical, focal nodular, and diffuse nodular. RESULTS: HSRT was delivered, most commonly 30 Gy in 5 fractions, to 320 intracranial lesions (57% intact and 43% surgical cavities) in 235 patients. The median follow-up was 13.4 months (range, 0.8 to 60 mo). LMD developed in 19% of patients with a 1-year LMD rate of 12%. From the diagnosis of LMD, the median overall survival (OS) was 3.8 months (range, 2-20.8 mo). The most common LMD pattern was diffuse nodular (44%). No difference in OS was observed between LMD patterns (P = 0.203). Multivariable analysis identified surgical cavities at significantly higher risk of LMD compared with intact lesions (odds ratio [OR] = 2.30, 95% CI: 1.24, 4.29, P = 0.008). For cavities, radiosensitive tumors (OR = 2.35, 95% CI: 1.04, 5.35, P = 0.041) predicted for LMD, while, for intact metastases, patients receiving treatment with targeted agents or immunotherapy (TA/I) were at lower risk (OR = 0.178, 95% CI: 0.04, 0.79, P = 0.023). CONCLUSIONS:Patients who had a brain metastasis resected were at an increased risk of LMD. OS was poor despite treatment of LMD, and no differences in OS based on the pattern of LMD was observed. Treatment with TA/I was observed to be protective against LMD and requires further study.
Authors: Marc Chamberlain; Riccardo Soffietti; Jeffrey Raizer; Roberta Rudà; Dieta Brandsma; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Larry Junck; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle Journal: Neuro Oncol Date: 2014-05-27 Impact factor: 12.300
Authors: Roshan S Prabhu; Brandon E Turner; Anthony L Asher; Samuel R Marcrom; John B Fiveash; Paul M Foreman; Robert H Press; Kirtesh R Patel; Walter J Curran; William G Breen; Paul D Brown; Krishan R Jethwa; Inga S Grills; Jessica D Arden; Lauren M Foster; Matthew A Manning; Joseph D Stern; Scott G Soltys; Stuart H Burri Journal: Neuro Oncol Date: 2019-08-05 Impact factor: 12.300
Authors: Diana Steinmann; Bettina Maertens; Stefan Janssen; Martin Werner; Jörg Frühauf; Makoto Nakamura; Hans Christiansen; Michael Bremer Journal: J Cancer Res Clin Oncol Date: 2012-04-24 Impact factor: 4.553
Authors: Ido Strauss; Benjamin W Corn; Vibhor Krishna; Tal Shahar; Diana Matceyevsky; Elijahu Gez; Natan Shtraus; Zvi Ram; Andrew A Kanner Journal: World Neurosurg Date: 2015-08-14 Impact factor: 2.104
Authors: Kirtesh R Patel; Stuart H Burri; Anthony L Asher; Ian R Crocker; Robert W Fraser; Chao Zhang; Zhengjia Chen; Shravan Kandula; Jim Zhong; Robert H Press; Jeffery J Olson; Nelson M Oyesiku; Scott D Wait; Walter J Curran; Hui-Kuo G Shu; Roshan S Prabhu Journal: Neurosurgery Date: 2016-08 Impact factor: 4.654
Authors: Robert H Press; Chao Zhang; Mudit Chowdhary; Roshan S Prabhu; Matthew J Ferris; Karen M Xu; Jeffrey J Olson; Bree R Eaton; Hui-Kuo G Shu; Walter J Curran; Ian R Crocker; Kirtesh R Patel Journal: Neurosurgery Date: 2019-11-01 Impact factor: 4.654
Authors: Daniel N Cagney; Nayan Lamba; Sumi Sinha; Paul J Catalano; Wenya Linda Bi; Brian M Alexander; Ayal A Aizer Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777
Authors: Andrew J Huang; Karen E Huang; Brandi R Page; Diandra N Ayala-Peacock; John T Lucas; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2014-07-22 Impact factor: 4.130
Authors: Eduardo M Marchan; Jennifer Peterson; Terence T Sio; Kaisorn L Chaichana; Anna C Harrell; Henry Ruiz-Garcia; Anita Mahajan; Paul D Brown; Daniel M Trifiletti Journal: Front Oncol Date: 2018-08-31 Impact factor: 6.244
Authors: Paolo Palmisciano; Ali S Haider; Chibueze D Nwagwu; Waseem Wahood; Kenny Yu; Chibawanye I Ene; Barbara J O'Brien; Salah G Aoun; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh Journal: Anticancer Res Date: 2021-11 Impact factor: 2.435
Authors: Desmond A Brown; Victor M Lu; Benjamin T Himes; Terry C Burns; Alfredo Quiñones-Hinojosa; Kaisorn L Chaichana; Ian F Parney Journal: Clin Exp Metastasis Date: 2020-01-16 Impact factor: 5.150
Authors: Ishaan Ashwini Tewarie; Charissa A C Jessurun; Alexander F C Hulsbergen; Timothy R Smith; Rania A Mekary; Marike L D Broekman Journal: Neurooncol Adv Date: 2021-11-10